The Evolving Peptide Revolution With Jim LaValle, RPh, CCN (Performance & Longevity Series)| LTTalks
Guest appearances — Jim LaValle, RPh — The Evolving Peptide Revolution With Jim LaValle, RPh, CCN (Performance & Longevity Series)| LTTalks
Channel: Life Time · Our label: Guest appearance — Jim LaValle, RPh as guest on host channels. The host channel is named on every page. · Source: youtube.com/watch?v=kb48OHzeHhE
Guest appearance: Jim LaValle, RPh appears as a guest on Life Time. This page is filed under the host channel and tagged as a guest appearance in our library.
What this video covers
Welcome to Life Time Talks and our series on performance and longevity with . I’m Jamie Martin and I’m here with my colleague and friend, Jim LaValle. He’s a clinical pharmacist, the co-chair of the American Academy of Anti-Aging Medicine, the chair of the International Peptide Society, and the Chief Science Officer at Life Time. I’m excited for this episode because this is we’re doing a deep dive into peptides and their evolution.
Summary drawn from this video’s own transcript (banked in our research library, pulled 2026-11-07). Claims below are the speaker’s — attributed, not endorsed. This site publishes no dosing, protocol, or sourcing information.
Key points, in the speaker’s own framing
- So when I think of peptides, I think of the the latest tool in our toolkit to help people maintain health.
- And re so it doesn’t have to be a clinical trial in order to present it to the FDA.
- Even though there’s not a large body of evidence in the literature for humans, there’s very slight for humans, there’s all these docs that have all this clinical evidence that people repair quicker, they heal faster.
- And you know, I talked to the law firms that are at the FDA and are at the Department of Health and Human Services trying to get guidance on hey, what’s what’s happening?
- Let’s all work together to make them safe for everybody and have them safely in the FDA’s, you know, policies where you’re allowed to make them.
- GLP one, GLP two activity, myostatin inhibition, which means you’re gonna maintain mass, you’re not gonna lose mass, and it also showed less inflammatory signaling in the gut.
Read next
Educational information only — not medical advice. Peptides discussed on this page include substances that are not FDA-approved.